Ultrasound Based Study For Niche Development In The Uterine Cesarean Section Scar
Launched by CAIRO UNIVERSITY · Feb 27, 2019
Trial Information
Current as of June 20, 2025
Completed
Keywords
ClinConnect Summary
Cesarean delivery is amongst the most widely recognized operations performed on women and its rate continue expanding. The rates of cesarean section (CS) in the United States in 1996 and 2009 were 20.7% and 32.3% respectively, witnessing an expansion of more than half. In China, 50% of deliveries in 2010 were through CS. In the Netherlands, the cesarean delivery rate jumped from 7.4 to 15.8% between 1990 and 2008, whereas in the United Kingdom, the CS rate increased from 12 to 29% throughout the same time period. In Brazil, the CS rate jumped from 15% in 1970 to even 80% in 2004.
The expan...
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • 1. Cases are delivered by Lower segment cesarean section
- • 2. Controls are delivered vaginally
- • 3. Singleton fetus
- • 4. Living fetus
- • 5. Term pregnancy
- Exclusion Criteria:
- • 1. Placenta praevia
- • 2. Congenital fetal anomalies
- • 3. Severe oligohydramnios(MVP \<2cm)
- • 4. Rupture of membranes more than 18 hours
- • 5. Puerperal pyrexia or sepsis
- • 6. Bladder injury
- • 7. Blood transfusion
About Cairo University
Cairo University, a premier institution in Egypt, is dedicated to advancing medical research and education through innovative clinical trials. With a strong emphasis on improving healthcare outcomes, the university collaborates with various stakeholders to conduct rigorous scientific studies that address critical health challenges. Leveraging its extensive resources and expert faculty, Cairo University aims to contribute valuable insights to the medical community and enhance patient care both locally and globally. Through its commitment to ethical research practices and excellence, the university plays a pivotal role in shaping the future of healthcare in the region.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Cairo, , Egypt
Cairo, , Egypt
Patients applied
Trial Officials
Mona M Aboulghar, M.D.
Principal Investigator
Cairo University
Hassan M Gaafar, M.D.
Principal Investigator
Cairo University
Hisham M Haggag, M.D.
Principal Investigator
Cairo University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials